Therapy News and Research

RSS

New research reveals key steps in HIV's assault on the brain

Scientists have unraveled in unprecedented detail the cascade of events that go wrong in brain cells affected by HIV, a virus whose assault on the nervous system continues unabated despite antiviral medications that can keep the virus at bay for years in the rest of the body.

16 Nov 2008

Proton therapy may reduce serious side effect of lung cancer treatment

Patients with locally advanced lung cancer who receive chemotherapy and proton therapy, a specialized form a radiation therapy only available in a few centers in the United States, have fewer instances of a serious side effect called bone marrow toxicity than patients who receive chemotherapy and another type of radiation therapy called intensity modulated radiation therapy (IMRT), according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

PEA-15 protein points to potential targeted approach for ovarian cancer

A protein known to inhibit the growth of ovarian cancer works in part by forcing cancer cells to eat themselves until they die, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 15 issue of Cancer Research .

16 Nov 2008

Previously unknown regulatory step during HIV replication provides potential new target for HIV/AIDS therapy

A previously unknown regulatory step during human immunodeficiency (HIV) replication provides a potentially valuable new target for HIV/AIDS therapy, report researchers at the Salk Institute for Biological Studies and the University of Wisconsin, Madison.

16 Nov 2008

Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment

The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.

16 Nov 2008

Gender found to be play important role as a prognostic factor in people diagnosed with lung cancer

Even though some combinations of gender, race and/or marital status can factor into the overall survival of nonoperative non-small cell lung cancer patients, gender is the most significant factor impacting overall survival, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

Doctors' questions about end-of-life legalities may result in patient pain

When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies.

16 Nov 2008

Traditional chemotherapy agents with targeted therapies improves survival in advance-stage lung cancer

The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

Breast and prostate cancer treatment may result in bone loss

A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss.

16 Nov 2008

Advanced lung cancer patients see improved, progression-free survival

Patients with advanced non-small cell lung cancer whose disease has progressed following chemotherapy have a higher rate of tumor shrinkage and a longer interval before cancer progression when bevacizumab is added to standard second-line erlotinib therapy, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

Genetic Immunity announces first patient dosed in trial with DermaVir patch for HIV

Genetic Immunity, a US/Hungarian clinical-stage company focused on development of nanomedicines for targeted immune amplification, today announced it has treated the first subject in a Phase II clinical study to evaluate DermaVir Patch.

13 Nov 2008

Osteoporosis drugs may prevent future bone growth

Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced stage osteoporosis. PTH has been proven to increase the volume and strength of the honeycomb-like bone infrastructure, the inner mesh that begins to diminish in old age.

13 Nov 2008

A new method to control bleeding in hemophilia

Investigators at Children's Research Institute, BloodCenter of Wisconsin's Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient's own platelets.

13 Nov 2008

Rosuvastatin trial shows dramatic reduction in hidden heart disease

A Harvard-led study shows that the risk of heart attack and stroke among subjects with "silent heart disease" - and normal cholesterol levels - can be dramatically reduced by the use of an already widely prescribed class of drugs.

13 Nov 2008

Doctors' questions about end-of-life legalities may result in patient pain

When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies. However, a team of researchers from Wake Forest University Baptist Medical Center, University of Rochester Medical Center and Unity Health System, report that a lack of thorough understanding about the laws governing end-of-life care may be leaving many medical providers with an ethical dilemma and causing some terminally-ill patients considerable, unnecessary pain.

13 Nov 2008